Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 11/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134378 | 1.00 | C3AR1 (0.47) | C3AR1PYGLCPB2MMP2MMP9 | |
| Bromide SCHEMBL4992858 | 0.99 | C3AR1 (0.46) | C3AR1PYGLCPB2MMP2MMP9 | |
| Bromide SCHEMBL4986289 | 0.99 | C3AR1 (0.46) | C3AR1PYGLCPB2MMP2MMP9 | |
| SCHEMBL4439606 | 0.97 | C3AR1 (0.46) | C3AR1PYGLCPB2MMP2MMP9 | |
| SCHEMBL4992916 | 0.93 | C3AR1 (0.44) | C3AR1 | |
| SCHEMBL4430852 | 0.90 | C3AR1 (0.46) | C3AR1 | |
| SCHEMBL14090933 | 0.89 | CNR2 (0.46) | C3AR1ERAP2LNPEPERAP1 | |
| SCHEMBL27772086 | 0.89 | C3AR1 (0.48) | C3AR1PYGLCPB2MMP2MMP9 | |
| SCHEMBL27793101 | 0.89 | C3AR1 (0.46) | C3AR1PYGLCPB2MMP2MMP9 | |
| SCHEMBL4437670 | 0.87 | KMT2A (0.46) | C3AR1PYGLMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101611008-A | C3A receptor modulators and methods of use thereof | ENCYSIVE PHARMACEUTICALS INC (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | C3AR1 1/4885PYGL 1070/4885CPB2 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.